Atara sells cell therapy manufacturing facility to Fujifilm for $100M; preliminary cash $371.1M

Atara Biotherapeutics, Inc.

Fujifilm to acquire ATOM facility for $100M upfront; closing expected April 2022.
Preliminary cash, equivalents & short-term investments of $371.1M as of Dec 31, 2021.
Transaction plus existing cash expected to fund planned operations into Q4 2023.
COO Joseph Newell transitions to consultant effective Jan 31, 2022; receives severance of 12 months' salary.
Parties enter long-term supply agreement (up to 10 years) for clinical/commercial manufacturing.

item 1.01 item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Newell

Executive Vice President and Chief Operations Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2022-01-31
Filed: January 26, 2022, 6:59 PM ET

In connection with the entry into the Asset Purchase Agreement and effective as of January 31, 2022, Joseph Newell, the Company’s Executive Vice President and Chief Operations Officer, will transition from being an employee of the Company and become a consultant.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Newell changed role as Executive Vice President and Chief Operations Officer at Atara Biotherapeutics, Inc..

Action: transitioned
Role: Executive Vice President and Chief Operations Officer

Exact text from the filing

In connection with the entry into the Asset Purchase Agreement and effective as of January 31, 2022, Joseph Newell, the Company’s Executive Vice President and Chief Operations Officer, will transition from being an employee of the Company and become a consultant.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-018422

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.